Post-earnings recap
Reported
Mon, May 4, 2026
EPS actual
$-1.28
EPS est.
$-1.14
EPS surprise
-12.38%
1-day move
+3.78%
CRISPR Therapeutics reported a larger-than-expected loss per share, which typically raises concerns among investors. However, the stock reacted positively, increasing by 3.78%. This could indicate that investors are looking beyond the EPS miss, possibly due to other factors not disclosed in the earnings call.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.28 | N/A | -12.38% |
| Revenue | N/A | N/A | N/A |
No transcript is on record, and the analysis is based on numerical results only.
CRISPR Therapeutics AG is a biotechnology company focused on developing transformative gene-based medicines for serious diseases. Operating in the healthcare sector, it aims to leverage CRISPR technology to create innovative therapies, which could significantly impact treatment options for genetic disorders and other conditions.
Last quarter
In Q4 2025, CRISPR reported an EPS of -$1.37, which was worse than analysts' expectations, leading to a slight stock increase the following day. The company continues to face challenges in meeting revenue expectations.
EPS beat streak
1Q
EPS beat rate
50%
Avg EPS surprise
-1.76%
Avg 1-day reaction
+0.23%
Investors are cautious ahead of the earnings report, given the company's mixed performance in previous quarters. The lack of analyst estimates adds uncertainty to expectations.
Bull case
If CRISPR can demonstrate significant progress in its clinical trials or better-than-expected R&D efficiency, it could lead to a positive market reaction.
Bear case
Conversely, if the company fails to provide updates on key trials or continues to report larger-than-expected losses, it may lead to further declines in stock price.
The print will turn on these.
Q1
What updates can management provide on the progress of clinical trials?
Investors will be closely watching for any news that could indicate the potential success of upcoming therapies, as this could significantly impact the company's future.
Q2
How is the company managing its R&D expenditures in light of recent financial losses?
Understanding how CRISPR is allocating its resources will be crucial for assessing its strategy and potential for recovery.
—
Est. EPS
$0.01
Est. Rev
$918M
Impl. Move
±9.1%
Why consensus could be wrong
The Street may be underestimating the potential impact of CRISPR's ongoing clinical trials, which could yield positive results not reflected in current expectations.
Supporting evidence
The options market is pricing an 11.29% move, indicating higher volatility expectations than historical averages.
The company's recent history shows a mixed EPS surprise rate, suggesting that the market may be overly cautious.
Previous quarters have shown that positive surprises can lead to significant stock movements, which may not be fully accounted for.
Key risk
If clinical trial results exceed expectations, it could shift market sentiment dramatically.
Pre-commit to what would confirm each case.
The market is debating whether CRISPR's innovative approach will translate into successful products, with recent performance raising concerns.
Bull confirmed if
Positive updates on clinical trials that indicate a high likelihood of success could validate the bull case.
Bear confirmed if
Continued losses and lack of progress in trials could confirm the bear case.
What the market is pricing for the move.
Implied Move
±11.29%
Historical Avg
±3.5%
The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.
Options are pricing ±11.3% while CRSP has averaged ±3.5% over the last 8 prints — setup is pricing rich.
ATM IV
0.7%
30d HV
59.1%
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing rich in Health Care
Fade rate: 6 of 19 (32%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 19 (68%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 6.5%, with a raw directional average of +3.2% (modestly positive historical bias).
Likely market behavior by outcome. Not investment advice.
Beat & raise
If CRISPR beats expectations with positive clinical trial updates, history suggests the stock could rise around 1.2% on average the next day.
In line / cautious
If results are in line but management expresses caution, the stock might see a muted reaction as investors digest the commentary.
Miss
A miss on earnings could lead to a decline of about 1.8% on average, as seen in previous quarters.
The lines on the call that would change the story.